Abstract 3015
Background
As an important tumor immunotherapy, the specificity and efficiency of PD1 inhibitor is not yet satisfactory. The treatment of solid tumor with mutant neoantigen specific T (MNaS-T) cells developed in this study is an adoptive cell therapy which is specific for each patient. The aim is to explore the difference in safety and efficacy between MNaS-T cells and PD1 inhibitors, and to evaluate the charateristic of immune repertoire (IR) as predictive biomarker.
Methods
A total number of 11 patients with advanced solid tumors who failed after multiline treatments were recruited. They were treated with MNaS-T cells, PD1 inhibitors and BSC; other 11 patients were treated with PD1 inhibitors and BSC as control. Peripheral blood was collected at baseline and per cycle (21-28d) respectively. Multiple PCR and NGS on TCR beta chain was used to detect IR.
Results
PFS of two groups had a statistical significance (P < 0.05), suggesting MNaS-T cells prolong patients' PFS. The safety was analyzed from routine blood urine stool test, coagulation function, liver and kidney function. There was no significant difference at baseline (P > 0.05). Compared with C group, total protein and albumin in T group had a transient decrease in 3rd, 4th and 5th follow-up respectively (P < 0.05), however, It can be recovered autonomously before 6th cycle. Evenness index and Clonality indexe were examined to illuminate the diversity and clonality of IR seperately. Compared to baseline, T cell repertoir of disease-progression patients and no-disease-progression patients after 1st cycle showed significantly different changes: Evenness 3.29 vs 0.85, P = 0.013; Clonality 0.76 vs 1.20, P = 0.015. Elevated Clonality may indicate amplification of tumor specific T cells which could recognize mutant neoantigen specifically.Table: 1163P
Demographic and clinical characteristics of 22 patients
| Characteristic | MNaS-T cells plus PD1 inhibitors plus BSC (N = 11) | PD1 inhibitors plus BSC (N = 11) | |||
|---|---|---|---|---|---|
| Disease Progression (N=4) | No Disease Progression (N=7) | Total (N = 11) | |||
| Age--no.(%) | |||||
| <60 | 4 (100) | 5 (71.4) | 9 (81.8) | 6 (54.5) | |
| > =60 | 0 | 2 (28.6) | 2 (18.2) | 5 (45.5) | |
| Sex--no.(%) | |||||
| Male | 3 (75) | 3 (42.9) | 6 (54.5) | 8 (72.7) | |
| Female | 1 (25) | 4 (57.1) | 5 (45.5) | 3 (27.3) | |
| Previous treatments--no. | |||||
| Chemotherapy | 4 | 7 | 11 | 11 | |
| Targeted therapy | 4 | 7 | 11 | 11 | |
| ECOG--no.(%) | |||||
| 0 | 0 | 0 | 0 | 0 | |
| 1 | 1 | 6 | 7 | 6 | |
| ≥2 | 3 | 1 | 4 | 5 | |
| Stage--no. | IV | 4 | 7 | 11 | 11 |
| Peripheral IR Diversity--mean (SD) | |||||
| Evenness | |||||
| Baseline | 0.01 (0.01) | 0.07 (0.08) | 0.05 (0.07) | ||
| 1st cycle | 0.05 (0.05) | 0.06 (0.07) | 0.05 (0.06) | ||
| 1st cycle / Baseline | 3.29 (2.09) | 0.85 (0.44) | 1.74 (1.71) | ||
| Clonality | |||||
| Baseline | 0.32 (0.09) | 0.25 (0.18) | 0.27 (0.15) | ||
| 1st cycle | 0.25 (0.12) | 0.27 (0.16) | 0.26 (0.14) | ||
| 1st cycle / Baseline | 0.76 (0.18) | 1.2 (0.27) | 1.04 (0.32) |
Conclusions
The combined immunotherapy of MNaS-T cells and PD1 inhibitors is more effective than PD1 inhibitor alone in prolonging the PFS, and has a good safety. IR Clonality change shows its potential as a predictive biomarker.
Clinical trial identification
Legal entity responsible for the study
J. Shunchang.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5964 - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence
Presenter: Karin Birkenkamp-Demtröder
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas
Presenter: Evgeny Imyanitov
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2422 - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
Presenter: Marzia Del Re
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2750 - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Presenter: Yulong Zheng
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2960 - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
Presenter: Jeff Bacher
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3791 - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Presenter: Zhenghang Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5189 - Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).
Presenter: Cinta Hierro
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5372 - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients
Presenter: Nicolas Brieu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
Presenter: Alice Bernard-Tessier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2287 - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Presenter: Marco Iafolla
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract